MAVENIR
14.12.2021 09:03:17 CET | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, announced today that Vodafone and Mavenir have completed the first data and Voice over LTE (VoLTE) call across a containerised 4G small cell Open RAN solution in a lab environment. The completed tests are the latest steps forward to delivering an open and vendor-interoperable 4G connectivity solution for small to medium-sized office locations.
Having first started work on a containerised indoor enterprise connectivity solution in January 2021, Vodafone has completed tests for an important stage of the technology roadmap. The plug-and-play small cell equipment can ensure comprehensive mobile coverage in every corner of the office. The solution will provide 4G coverage initially, making use of radio hardware from Sercomm and software from Mavenir (Open RAN).
This demonstration of a containerised solution is a major milestone in the evolution of connectivity equipment away from physical infrastructure to a digital cloud-based environment. Containerisation provides greater flexibility for customers, but also significant benefits in terms of speed and cost of deployment.
Containerisation means that software can be seamlessly transferred between equipment, platforms, and applications. Wind River provided its Containers as a Service (CaaS) software, part of Wind River Studio.
Moving forward, Vodafone and Mavenir will focus on finalising the packaging and automation of the solution before beginning trials with selected customers.
Open RAN technology separates software from hardware, meaning more flexibility for mobile operators and customers. The approach will see many companies providing the components that make up a mobile network site, where previously one vendor would have delivered the whole solution. The technology is widely accepted as a disruptor for the telecommunications industry, and Vodafone is one of the industry leaders in supporting the development of this vendor ecosystem.
Whereas much of the focus for Open RAN has been directed towards network infrastructure deployment on mobile sites throughout the UK, the technology can be implemented in an enterprise environment to support local connectivity requirements. As an interoperable and standardised technology, Open RAN solutions can be integrated with little disruption in a “plug and play” manner, interoperable with other Open RAN compliant vendors.
Andrea Dona, Chief Network Officer, Vodafone UK, said ; “Open RAN is opening doors to simplified and intuitive connectivity solutions. For our wider network deployment strategy, Open RAN is enabling us to work with a wider pool of suppliers and to avoid vendor lock-in scenarios that might prevent us from taking advantage of the latest innovations. The same could be said for enterprise connectivity solutions.
“From the moment Open RAN is deployed in an office environment, customers are no-longer locked into a single upgrade path. Working alongside Vodafone, customers can be more flexible in how connectivity solutions are adapted and upgraded as demands evolve in the future.”
Stefano Cantarelli, Executive Vice President and Chief Marketing Officer, Mavenir, said ; “Cloud Native and Open Solutions are becoming the new reality of the mobile world, and these include Radio Access and its containerised implementation. Open vRAN is a very flexible architecture that can serve any type of segment and Mavenir is really pleased to work with Vodafone in the enterprise business and achieved another first together. It is an opportunity to show that automated and AI controlled systems will simplify life to business and industry.”
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
About Vodafone UK
Vodafone UK is a technology communications company that connects people, businesses and devices to help our customers benefit from digital innovation. Our services span mobile, fixed-line connections, home and office broadband, and the Internet of Things (IoT). www.vodafone.co.uk
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214005101/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom